Lekast Tablet contains Levocetirizine 5mg and Montelukast 10mg, combining an antihistamine and a leukotriene receptor antagonist for the effective management of allergic conditions. Levocetirizine, a third-generation non-sedating antihistamine, selectively inhibits peripheral H1 receptors, thereby reducing symptoms such as sneezing, rhinorrhea, nasal congestion, and itching associated with allergic rhinitis and chronic urticaria. Montelukast, a selective leukotriene D4 receptor antagonist, blocks leukotriene-mediated bronchoconstriction, inflammation, and mucus production, making it effective in the prophylaxis and treatment of asthma and allergic rhinitis. The synergistic action of these agents provides comprehensive relief from allergic symptoms by targeting multiple inflammatory pathways. Lekast Tablet is indicated for the treatment of seasonal and perennial allergic rhinitis, chronic idiopathic urticaria, and as an adjunct therapy in asthma management to improve pulmonary function and reduce exacerbations. It is generally well tolerated; common adverse effects may include headache, fatigue, dry mouth, and gastrointestinal disturbances. Caution is advised in patients with hepatic or renal impairment. Lekast Tablet should be administered as prescribed by a healthcare professional, with adherence to recommended dosage to optimize therapeutic outcomes and minimize potential side effects.